{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/a4c5de36-8260-4222-8e38-ff997dc73436/66a272b122781665a9a2bb71?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Investing legends, Rentokil and AstraZeneca: The Companies and Markets Show","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b44742e856e989985776/1721920606416-09e45a406df346e5dcc45a53a513a8d8.jpeg?height=200","description":"<p>We begin with Mark Robinson who covers pest control business <a href=\"https://www.investorschronicle.co.uk/content/363d3e45-f788-5022-81bf-3a61c8ba63a4\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Rentokil (RTO)</strong></a><strong> </strong>which saw a double digit surge in its share price after rumours of private-equity takeovers began swirling.</p><p><br></p><p>It’s then on to this week’s cover story by James Norrington on the investing greats and how investors can apply their wisdom to their own portfolios.&nbsp;</p><p><br></p><p>Jennifer Johnson then joins the conversation with an update on leader of the FTSE 100, <a href=\"https://www.investorschronicle.co.uk/content/df6d9847-1aef-5561-9ccd-c264c2c9e219\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>AstraZeneca (AZN)</strong></a>. Why are shares down despite its guidance being upgraded? And what does the company offer outside of oncology drugs?</p><p><br></p><p>Last up, we cover energy company <a href=\"https://www.investorschronicle.co.uk/content/507b8d3c-9bb3-5058-8622-0584430e0189\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Centrica’s (CNA)</strong></a> results which received a less than favourable market reaction. </p><p><br></p><p>1:27 Rentokil (RTO)</p><p>12:53 Investing greats&nbsp;</p><p>23:50 AstraZeneca (AZN)</p><p>33:31 Centrica (CNA)</p><p><br></p><p>Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit <a href=\"http://www.investorschronicle.co.uk/podcasttrial\" rel=\"noopener noreferrer\" target=\"_blank\">www.investorschronicle.co.uk/podcasttrial</a>&nbsp;</p><p>*After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.</p><p><br></p><p><br></p>","author_name":"Investors' Chronicle"}